Advertisement

Sotorasib for KRAS G12C–Mutated NSCLC: CodeBreaK100 Trial
Posted: 05/10/2022 | By: Chase Doyle

Question 1 of 5

In the first analysis of the phase I/II CodeBreaK100 trial, what percentage of patients responded to sotorasib?

Choose 1

A
20.7%
B
30.7%
C
40.7%
D
50.7%

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage